DocWire News Editors

DocwireNews

A pre-meeting session at the annual meeting delved into the benefits and challenges of &ldquo;PROMIS Versus Legacy Data Instruments&rdquo; in collecting patient-reported outcomes (PROs) in rheumatology.Clifton O. Bingham III, MD, of the School of Medicine at Johns Hopkins University, said PROs can be used in clinical trials, observational studies, and clinical practice. Focusing on clinical practice, he said that the instruments practitioners use to measure PROs must be reliable, precise, fit for the purpose (e.g., more precision may be needed in clinical practice than in group studies), meaningful, actionable, and feasible.In preparation to compare the Patient-Reported Outcomes Measurement Information System (PROMIS) tool to legacy instruments, Dr. Bingham defined legacy data instruments as tools that have been traditionally used for measurement in a given condition. In rheumatoid arthritis (RA), he said most composite disease activity indices do not include all outcomes of concern to patients. &ldquo;Things we currently measure the most, pain and function, are important, but other outcomes like fatigue have been cited as important to patients, and we don&rsquo;t currently measure them,&rdquo; he said.Dr. Bingham specifically discussed the strengths and weaknesses of the global visual analog scale (VAS), pain VAS, Health Assessment Questionnaire Disability Index (HAQ-DI), RAPID-3, 36-Item Short Form Health Survey (SF-36), and Rheumatoid Arthritis Impact of Disease (RAID).VAS and numerical rating scales, although commonly used and simple to administer, may not adequately reflect a complex construct, and they may not be interval scales of measurement, he said. Although the HAQ-DI is the gold standard for physical function in trials and defines a minimally important difference (MID) for improvement, he continued, the instrument contains 20 questions, scoring is more difficult, content relevance and interpretation are troublesome for patients, and it may not provide enough information about patients with relatively good performance.The RAPID-3 is easily deployable, responsive in trials, and has established thresholds. But the score only reflects core domains, not all domains that patients have described as important. Dr. Bingham also reviewed the SF-36, which can be used across multiple disease states, is generic about health-related quality of life (QOL), and is responsive in clinical trials. However, the tool requires complex scoring and has a fee. Additionally, some of the concepts are &ldquo;nebulous,&rdquo; Dr. Bingham said, making it difficult to define actionability.Finally, he discussed RAID, which was derived from patients and what they identified as important, is easy to administer, and has simple scoring, but it has not been widely deployed in trials and observational studies, and responsiveness and minimally importance difference have not yet been well defined.Dr. Bingham then discussed PROMIS, which was developed to evaluate health-related QOL across physical, mental, and social health. It measures physical function, anxiety, depression, fatigue, pain interference, sleep disturbances, and satisfaction. Item banks reflect health domains applicable across disease states, and scales are reported as T scores. PROMIS uses computer-adapted testing and must be embedded in the computer system.A review of the literature has shown that the tool is highly responsive in measuring treatment effectiveness over time in individual patients with RA, a population particularly relevant to this meeting. Researchers also have started to use PROMIS to track fatigue in clinical trials of rheumatic conditions, including RA and systemic&nbsp;lupus&nbsp;erythematosus.In conclusion, Dr. Bingham stressed that tools that measure PROs should reflect areas of health that are most important to patients. They should perform well in clinical practice and allow actionable results. He believes that PROMIS represents an emerging system to measure PROs that may be applicable in multiple settings using a common metric.

Jordana Jampel

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Katie Kosko

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Latest News

The PROMIS of Measuring Patient-Reported Outcomes

ACR 2018 Conference

A pre-meeting session at the annual meeting delved into the benefits and challenges of “PROMIS Versus Legacy Data Instruments” in collecting patient-reported outcomes ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe